uniQure (NASDAQ:QURE) Reaches New 52-Week High – Here’s What Happened

uniQure N.V. (NASDAQ:QURE) reached a new 52-week high on Tuesday . The company traded as high as $59.83 and last traded at $59.40, with a volume of 8087824 shares. The stock had previously closed at $54.31.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on QURE shares. Stifel Nicolaus increased their price target on uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. The Goldman Sachs Group increased their target price on uniQure from $13.00 to $56.00 and gave the company a “neutral” rating in a research report on Thursday, September 25th. Guggenheim lifted their price target on uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. Chardan Capital upped their price objective on uniQure from $35.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. Finally, UBS Group set a $95.00 target price on shares of uniQure in a research report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, uniQure currently has an average rating of “Buy” and an average price target of $67.17.

uniQure Stock Performance

The stock has a 50 day moving average of $20.01 and a 200 day moving average of $15.80. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of -14.03 and a beta of 0.54. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.20. The business had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. As a group, analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 226,316 shares of the business’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the transaction, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at $27,009,282.84. The trade was a 25.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Christian Klemt sold 15,000 shares of the company’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $55.00, for a total value of $825,000.00. Following the sale, the chief financial officer owned 217,730 shares in the company, valued at approximately $11,975,150. The trade was a 6.45% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 244,316 shares of company stock worth $10,328,181. 4.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP grew its position in shares of uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock worth $50,801,000 after buying an additional 1,767,572 shares during the period. Nantahala Capital Management LLC boosted its stake in uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock worth $29,213,000 after acquiring an additional 101,598 shares in the last quarter. Aberdeen Group plc grew its holdings in uniQure by 24.2% in the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after purchasing an additional 535,163 shares during the period. Jefferies Financial Group Inc. acquired a new stake in uniQure in the second quarter worth $29,217,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after purchasing an additional 1,491,486 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.